Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idecabtagene vicleucel (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Daratumumab; Dexamethasone; Dexamethasone; Elotuzumab; Ixazomib; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms KarMMa-3
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 04 Jun 2024 Results assessing 3 prototype models for risk of developing high-grade iAEs after ide-cel infusion, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results assessing pre- and post-tx pt factors and pharmacodynamic biomarkers associated with longer PFS with ide-cel in the treated population , presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 23 May 2024 According to Bristol Myers Squibb media release, the company announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top